Patara Pharma Closes a $26 million Series A Financing and Initiates Phase II Clinical Trials to Evaluate PA101B for Refractory Chronic Cough and Indolent Systemic Mastocytosis
You will be directed to a different website or mobile app that has its own terms of use, visitor agreement, security and privacy policies. SVB is not responsible for (and does not provide) any products, services or content at the third party site or app, except for the products and services that carry the SVB name.
